Article Details

CSL invests $313m to bulk up flu, COVID-19 mRNA tech - AFR

Retrieved on: 2022-11-02 01:25:47

Tags for this article:

Click the tags to see associated articles and topics

CSL invests $313m to bulk up flu, COVID-19 mRNA tech - AFR. View article details on hiswai:

Excerpt

Blood products giant CSL is investing a minimum of $US200 million ($313 million) in beefing up its mRNA capabilities, spanning the flu, ...

Article found on: www.afr.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up